Today ChanTest announces the hiring of Chris Mathes, Ph.D., M.B.A. to lead its 
business into a new era. Mathes starts September 1st as Chief Commercial 
Officer (CCO) and will oversee all sales, marketing and customer relations 
activities at ChanTest. He will also contribute to the forward looking and 
strategic guidance of ChanTest as a global player in the CRO industry.

(Photo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"Chris is a real ion channel guy," said Dr. Arthur "Buzz" Brown, CEO, President 
& Founder of ChanTest. "As CCO, he brings a unique mix of science and business 
to our company in order to make ChanTest's interface to the world even better."

Dr. Mathes has a Ph.D. in Neuroscience from UCLA and an MBA from Rutgers 
University. He has published several ion channel papers in peer reviewed 
journals over the past two decades. In the last 10 years, Mathes has been a 
pioneer in the development and implementation of automated patch clamp systems 
for ion channel safety testing and drug discovery. 

"I'm really excited about this opportunity at ChanTest," Mathes said. "ChanTest 
is already the market leading ion channel CRO. My goal is to further enhance 
the brand and to expand the business. I want to make sure that every 
pharmaceutical or biotech lab in the world accesses the ion channel and 
scientific expertise available at ChanTest."

About ChanTest Corporation (www.chantest.com)

ChanTest translates the most advanced Ion Channel, GPCR and Transporter 
technologies to provide safer, more effective medicines. By combining 
electrophysiology, molecular biology and cell culture including cell lines, 
stem cells and native cells ChanTest has developed biomarkers, reagents and 
services that greatly enhance drug discovery. The Company has alliances in 
which its technologies are integrated with medicinal, combinatorial and 
computational chemistry, animal models and clinical trials to provide modular 
or complete services along the drug development pathway. Since its inception in 
1998, ChanTest has tested compounds for more than 500 global pharmaceutical and 
biotechnology companies. ChanTest's library of ion channel cell lines, 
validated human stem cell-derived cardiomyocytes and predictive nonclinical 
cardiac risk assessment program are the most comprehensive available today. 
Because of ChanTest's seminal role in cardiac safety and its uncompromising 
commitment to quality, ChanTest has been named the "most trusted and most used 
fee-for-service provider" for ion channel screening in an independent survey 
for the past three years. ChanTest is based in Cleveland, Ohio. For more 
information, e-mail info@chantest.com. 

CONTACT: Kate Siver, +1-216-332-1665, info@chantest.com

SOURCE:  ChanTest Corporation